James A. Schoeneck - 29 Mar 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role
Director
Signature
/s/ Andrew Jackson, Attorney-in-fact
Issuer symbol
CLDI
Transactions as of
29 Mar 2024
Net transactions value
$0
Form type
4
Filing time
02 Jul 2024, 20:14:26 UTC
Previous filing
04 Jan 2024
Next filing
22 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDI Common Stock Award +28,207 +2.9% 992,094 29 Mar 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") on March 29, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's first fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date.

Remarks:

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated April 22, 2024)